Yerneni Sharmitha, Murad Fadi, Schmults Chrysalyne D, Ruiz Emily S
Tufts University School of Medicine, Boston, Massachusetts.
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Dermatol Surg. 2023 Apr 1;49(4):317-321. doi: 10.1097/DSS.0000000000003705. Epub 2023 Jan 27.
Microcystic adnexal carcinoma (MAC) is a locally aggressive and deeply infiltrative cutaneous tumor primarily treated with excision; however, there are limited data comparing outcomes by surgical approach.
To compare surgical outcomes of MAC treated with Mohs micrographic surgery (MMS) and wide local excision (WLE).
A 27-year retrospective cohort study of primary MAC was performed. Surgical (i.e. margin status after resection) and recurrence outcomes (including local recurrence [LR], nodal metastases [NM], and distance metastases [DM]) were analyzed by type of surgical approach (MMS and WLE).
Sixty-nine MACs were included, of which 34 (49.3%) were treated with MMS and 35 (50.7%) with WLE. All MMS-treated tumors had negative margins after the first surgery attempt. Twenty-one (60.0%) tumors treated with WLE had positive margins after the first surgical attempt and required additional procedures. More tumors treated with WLE developed LR, NM, or DM, although this did not meet statistical significance.
Retrospective single institution study.
Greater than half of MAC tumors treated with WLE had positive margins after the initial surgery and required multiple procedures for complete removal. Real-time complete margin assessment is important for this locally aggressive and infiltrative tumor.
微囊性附属器癌(MAC)是一种具有局部侵袭性且浸润较深的皮肤肿瘤,主要通过手术切除进行治疗;然而,比较不同手术方式疗效的数据有限。
比较Mohs显微外科手术(MMS)和广泛局部切除(WLE)治疗MAC的手术效果。
对原发性MAC进行了一项为期27年的回顾性队列研究。通过手术方式(MMS和WLE)分析手术(即切除术后切缘状态)和复发结果(包括局部复发[LR]、区域淋巴结转移[NM]和远处转移[DM])。
纳入69例MAC,其中34例(49.3%)接受MMS治疗,35例(50.7%)接受WLE治疗。所有接受MMS治疗的肿瘤在首次手术尝试后切缘均为阴性。21例(60.0%)接受WLE治疗的肿瘤在首次手术尝试后切缘阳性,需要额外的手术。更多接受WLE治疗的肿瘤发生了LR、NM或DM,尽管这未达到统计学意义。
单机构回顾性研究。
超过半数接受WLE治疗的MAC肿瘤在初次手术后切缘阳性,需要多次手术才能完全切除。对于这种具有局部侵袭性和浸润性的肿瘤,实时完整切缘评估很重要。